Controversies in Breast Cancer Screening Strategies

Therese Bevers; Kirsten Bibbins-Domingo; Kevin C Oeffinger; Mary Lou Smith

doi:10.6004/jnccn.2016.0183

Controversies in Breast Cancer Screening Strategies

J Natl Compr Canc Netw. 2016 May;14(5 Suppl):651-3. doi: 10.6004/jnccn.2016.0183.

Authors

Therese Bevers¹, Kirsten Bibbins-Domingo¹, Kevin C Oeffinger¹, Mary Lou Smith¹

Affiliation

¹ Presented by Therese Bevers, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Chair of the NCCN Guidelines for Breast Cancer Screening and Diagnosis; Kirsten Bibbins-Domingo, PhD, MD, MAS, University of California, San Francisco, San Francisco, California, and Chair of the U.S. Preventive Services Task Force; and Kevin C. Oeffinger, MD, Memorial Sloan Kettering Cancer Center, New York, New York, and Chair of the American Cancer Society Breast Cancer Screening Guideline Panel; facilitated by Mary Lou Smith, JD, MBA, Research Advocacy Network, Naperville, Illinois.

PMID: 27226505
DOI: 10.6004/jnccn.2016.0183

Abstract

A panel discussion on controversies in breast cancer screening held recently at the NCCN 21st Annual Conference included only a few controversies. Representatives of the U.S. Preventive Services Task Force, American Cancer Society, and NCCN disagreed primarily on 2 main areas: when to start screening (ages 40, 45, or 50 years) and frequency of screening (annual vs biennial). Panelists from these organizations presented the rationales for their respective recommendations.

MeSH terms

Breast Neoplasms / diagnosis*
Early Detection of Cancer
Female
Humans
Mass Screening / methods*
Middle Aged